Alcon (ALC) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Apr, 2026Executive summary
Fourth quarter 2025 net sales reached $2.7 billion, up 9% year-over-year, driven by new product launches and innovation, with full-year net sales at $10.3 billion, up 5% from 2024.
Core diluted EPS for Q4 was $0.78 (up 8% year-over-year), while reported diluted EPS was $0.44 (down 23% year-over-year); full-year core diluted EPS was $3.07, flat year-over-year.
Generated $2.3 billion in operating cash flow and $1.7 billion in free cash flow for the year.
The company remains focused on disciplined investment, cost optimization, and shareholder returns.
Financial highlights
Q4 2025 core operating margin was 19.0%, down 110 bps year-over-year; full-year core operating margin was 19.8%, down 90 bps.
Q4 2025 IFRS operating margin was 11.6%, down 430 bps year-over-year; full-year IFRS operating margin was 13.2%.
Q4 core gross margin was 62.5%; full-year core gross margin was 62.7%.
EBITDA for 2025 was $2.68 billion, up from $2.63 billion in 2024.
$848 million returned to shareholders in 2025 via $682 million in share repurchases and $166 million in dividends.
Outlook and guidance
2026 net sales growth expected at 5–7% (constant currency), with core operating margin up 70–170 bps and core diluted EPS growth of 9–12%.
Full-year tariff impact expected to be $125–175 million, pressuring cost of sales; average tariff rate of 15% assumed for 2026.
Core effective tax rate for 2026 projected at ~20%.
Efficiency measures to deliver $100 million in annualized savings, with $50 million realized in 2026 at a $150 million total cost.
Dividend of 28 Swiss centimes per share proposed, in line with payout policy.
Latest events from Alcon
- Q2 sales up 3% to $2.5B, led by innovation and global growth; FY24 guidance reaffirmed.ALC
Q2 20241 Feb 2026 - Q3 saw 6% sales growth, record cash flow, and strategic portfolio actions.ALC
Q3 202414 Jan 2026 - Strong sales, innovation, and new launches drive above-market growth in eye care.ALC
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Major US launches in eye care and surgical devices set to drive growth and efficiency.ALC
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Net sales up 5–6% to $9.8B, core EPS up 16%, and free cash flow more than doubled.ALC
Q4 20247 Jan 2026 - Q3 2025 sales up 6% year-over-year; margin guidance maintained amid tariff and tax pressures.ALC
Q3 202515 Dec 2025 - Aiming for 6%-8% sales and 12%-15% EPS growth, driven by innovation and operational excellence.ALC
CMD 20255 Dec 2025 - Alcon to acquire STAAR Surgical for $1.5B in cash, pending regulatory and shareholder approval.ALC
Proxy Filing2 Dec 2025 - Q2 2025 sales up 4% to $2.6B; growth driven by Vision Care, new launches, and acquisitions.ALC
Q2 202529 Nov 2025